PSTX News and Press, Poseida Therapeutics Inc. From 03/01/22

Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO , March 1, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineer...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations Virtual R&D...

Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy PR Newswire SAN DIEGO , Feb. 22, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform techn...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Febr...

Gainers: Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. Outset Medical (NASDAQ:OM) +10%. Masimo (NASDAQ:MASI) +8%. Vivos Therapeutics (NASDAQ:VVOS) +7%. Losers: 10x Genomics (NASDAQ:TXG) -16%. iSpecimen ISPC -10%. Poseida ...

Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium P-PSMA-101 demonstrated strong anti-tumor activity and induced durable responses at low doses in heavily pretreated patients with mCRPC 10/14 (71%) evalua...

Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022 Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022 PR Newswire SAN DIEGO , Feb. 9, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage b...

Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors PR Newswire SAN DIEGO , Dec. 20, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), ...

Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting P-BCMA-101 demonstrated strong anti-tumor activity and was well tolerated in nearly 100 patients with R/R multiple myeloma at the time of d...